Mersana Therapeutics Inc MRSN.OQ MRSN.O is expected to show a rise in quarterly revenue when it reports results on August 13 for the period ending June 30 2025
The Cambridge Massachusetts-based company is expected to report a 177.5% increase in revenue to $6.363 million from $2.29 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Mersana Therapeutics Inc is for a loss of $3.93 per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Mersana Therapeutics Inc is $137.50, about 95.2% above its last closing price of $6.61
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -4.52 | -4.85 | -4.75 | Beat | 2.1 |
Dec. 31 2025 | -4.04 | -4.03 | -2.75 | Beat | 31.7 |
Sep. 30 2024 | -4.38 | -4.39 | -2.25 | Beat | 48.7 |
Jun. 30 2024 | -4.28 | -4.29 | -5.00 | Missed | -16.7 |
Mar. 31 2024 | -4.38 | -4.52 | -4.00 | Beat | 11.6 |
Dec. 31 2023 | -3.03 | -4.11 | -4.00 | Beat | 2.6 |
Sep. 30 2023 | -8.78 | -9.05 | -6.75 | Beat | 25.4 |
Jun. 30 2023 | -9.34 | -11.04 | -11.75 | Missed | -6.5 |
This summary was machine generated August 8 at 15:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。